Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor

Kazumi Koga, Mitsukane Yoshinaga, Yoshikatsu Uematsu, Yuji Nagai, Naoki Miyakoshi, Yoko Shimoda, Masayuki Fujinaga, Takafumi Minamimoto, Ming-Rong Zhang, Makoto Higuchi, Norikazu Ohtake, Tetsuya Suhara and Shigeyuki Chaki
Journal of Pharmacology and Experimental Therapeutics June 2016, 357 (3) 495-508; DOI: https://doi.org/10.1124/jpet.116.232942
Kazumi Koga
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitsukane Yoshinaga
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshikatsu Uematsu
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuji Nagai
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoki Miyakoshi
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoko Shimoda
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masayuki Fujinaga
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takafumi Minamimoto
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Rong Zhang
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto Higuchi
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norikazu Ohtake
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tetsuya Suhara
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeyuki Chaki
Pharmacology Laboratories (K.K., Y.U., S.C.) and Chemistry Laboratories (M.Y., N.M., N.O.), Taisho Pharmaceutical Co., Ltd., Saitama, Japan; and Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, Japan (Y.N., Y.S., M.F., T.M., M.-R.Z., M.H., T.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A novel pyridopyrimidin-4-one derivative, N-tert-butyl-2-[2-(3-methoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]acetamide (TASP0434299), was characterized as a radioligand candidate for arginine vasopressin 1B (V1B) receptor. TASP0434299 exhibited high binding affinities for human and rat V1B receptors with IC50 values of 0.526 and 0.641 nM, respectively, and potent antagonistic activity at the human V1B receptor with an IC50 value of 0.639 nM without apparent binding affinities for other molecules at 1 μM. [3H]TASP0434299 bound to membranes expressing the human V1B receptor as well as those prepared from the rat anterior pituitary in a saturable manner. The binding of [3H]TASP0434299 to the membranes was dose-dependently displaced by several ligands for the V1B receptor. In addition, the intravenous administration of [3H]TASP0434299 to rats produced a saturable radioactive accumulation in the anterior pituitary where the V1B receptor is enriched, and it was dose-dependently blocked by the oral administration of 2-[2-(3-chloro-4-fluorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]-N-isopropylacetamide hydrochloride, a V1B receptor antagonist, indicating that [3H]TASP0434299 can be used as an in vivo radiotracer to measure the occupancy of the V1B receptor. Finally, the intravenous administration of [11C]TASP0434299 provided positron emission tomographic images of the V1B receptor in the pituitary in an anesthetized monkey, and the signal was blocked by pretreatment with an excess of unlabeled TASP0434299. These results indicate that radiolabeled TASP0434299 is the first radioligand to be capable of quantifying the V1B receptor selectively in both in vitro and in vivo studies and will provide a clinical biomarker for determining the occupancy of the V1B receptor during drug development or for monitoring the levels of the V1B receptor in diseased conditions.

Footnotes

    • Received February 16, 2016.
    • Accepted March 28, 2016.
  • This study was funded by Taisho Pharmaceutical Co., Ltd. This study was supported in part by the Brain Mapping by Integrated Neurotechnologies for Disease Studies (to T.S.) from the Japan Agency for Medical Research and Development, and by Grants-in-Aid for Scientific Research on Innovative Areas [Brain Environment Grant 23111009] (to M.H.) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

  • K.K., M.Y., Y.U., N.M., N.O., and S.C. are full-time employees of Taisho Pharmaceutical Co., Ltd.

  • dx.doi.org/10.1124/jpet.116.232942.

  • Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 357 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 357, Issue 3
1 Jun 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
TASP0434299: A Novel Pyridopyrimidin-4-One Derivative as a Radioligand for Vasopressin V1B Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

A Novel Radioligand for Vasopressin V1B Receptor

Kazumi Koga, Mitsukane Yoshinaga, Yoshikatsu Uematsu, Yuji Nagai, Naoki Miyakoshi, Yoko Shimoda, Masayuki Fujinaga, Takafumi Minamimoto, Ming-Rong Zhang, Makoto Higuchi, Norikazu Ohtake, Tetsuya Suhara and Shigeyuki Chaki
Journal of Pharmacology and Experimental Therapeutics June 1, 2016, 357 (3) 495-508; DOI: https://doi.org/10.1124/jpet.116.232942

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

A Novel Radioligand for Vasopressin V1B Receptor

Kazumi Koga, Mitsukane Yoshinaga, Yoshikatsu Uematsu, Yuji Nagai, Naoki Miyakoshi, Yoko Shimoda, Masayuki Fujinaga, Takafumi Minamimoto, Ming-Rong Zhang, Makoto Higuchi, Norikazu Ohtake, Tetsuya Suhara and Shigeyuki Chaki
Journal of Pharmacology and Experimental Therapeutics June 1, 2016, 357 (3) 495-508; DOI: https://doi.org/10.1124/jpet.116.232942
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucose transport modulators and mouse behavioral testing
  • Translational PK/PD Modeling of M3258
  • Kidney protective effects of BI 685509
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics